Advertisement

Journal of Neuro-Oncology

, 89:313 | Cite as

Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults

  • John Buatti
  • Timothy C. Ryken
  • Mark C. Smith
  • Penny Sneed
  • John H. Suh
  • Minesh Mehta
  • Jeffrey J. Olson
Invited Manuscript

Recommendations

Level 1

Radiation therapy is recommended for the treatment of newly diagnosed malignant glioma in adults. Treatment schemes should include dosage of up to 60 Gy given in 2 Gy daily fractions that includes the enhancing area.

Hypo-fractionated radiation schemes may be used for patients with a poor prognosis and limited survival without compromising response.

Hyper-fractionation and accelerated fractionation have not been shown to be superior to conventional fractionation and are not recommended.

Brachytherapy or stereotactic radiosurgery as a boost to external beam radiotherapy have not been shown to be beneficial and are not recommended in the routine management of newly diagnosed malignant glioma.

Level 2

It is recommended that radiation therapy planning include a 1–2 cm margin around the radiographically defined T1 contrast-enhancing tumor volume or the T2 weighted abnormality on MR imaging.

Rationale

Although radiation therapy has been a standard therapy for the...

Keywords

Malignant Glioma Karnofsky Performance Status BCNU Radiation Therapy Oncology Group Brain Radiotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We wish to acknowledge Stephen Haines, MD, Jack Rock, MD, and Tom Mikkelson, MD for their review and consultations regarding on this work. The authors also wish to express appreciation to the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions. We also thank Linda Phillips for meeting organization and collection of materials and Emily Feinstein for her assistance in editing the material for publication.

References

  1. 1.
    Neuro-oncology Disease Site Group et al (2004) Radiotherapy for newly diagnosed malignant glioma in adults. Practice Guideline Report 9-3Google Scholar
  2. 2.
    Shapiro WR, Young DF (1976) Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol 33(7):494–550PubMedGoogle Scholar
  3. 3.
    Walker MD et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333–343PubMedGoogle Scholar
  4. 4.
    Walker MD et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303(23):1323–1329Google Scholar
  5. 5.
    Kristiansen K et al (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4):649–652PubMedCrossRefGoogle Scholar
  6. 6.
    Sandberg-Wollheim M et al (1991) A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1):22–29PubMedCrossRefGoogle Scholar
  7. 7.
    Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273PubMedCrossRefGoogle Scholar
  8. 8.
    Andersen AP (1978) Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 17(6):475–484 PubMedGoogle Scholar
  9. 9.
    Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64(4):769–774PubMedGoogle Scholar
  10. 10 .
    Nelson DF et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma–possible advantage observed at 72.0 Gy in 1.2 Gy B·I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25(2):193–207PubMedGoogle Scholar
  11. 11.
    Chang CH et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52(6):997–1007PubMedCrossRefGoogle Scholar
  12. 12.
    Nelson DF et al (1988) Combined modality approach to treatment of malignant gliomas—reevaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988(6):279–284Google Scholar
  13. 13.
    Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731 PubMedGoogle Scholar
  14. 14.
    Lee S et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88PubMedGoogle Scholar
  15. 15.
    Massey V, Wallner K (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398PubMedGoogle Scholar
  16. 16.
    Wallner K et al (1989) Patterns of failure following treatment for glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMedGoogle Scholar
  17. 17.
    Shapiro WR et al (1989) Randomized trial of three chemotherapy regimens, two radiotherapy regimens, two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71(1):1–9PubMedGoogle Scholar
  18. 18.
    Kita M et al (1989) Radiotherapy of malignant glioma–prospective randomized clinical study of whole brain vs. local irradiation. Gan No Rinsho 35(11):1289–1294PubMedGoogle Scholar
  19. 19.
    Phillips C et al (2003) A randomized trial comparing 35 Gy in ten fractions with 60 Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 68(1):23–26PubMedCrossRefGoogle Scholar
  20. 20.
    Prados MD et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49(1):71–77PubMedGoogle Scholar
  21. 21.
    Deutsch M et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. International Int J Rad Oncol Biol Phys 16(6):1389–1396Google Scholar
  22. 22.
    Ludgate CM et al (1988) Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Rad Oncol Biol Phys 15(5):1091–1095Google Scholar
  23. 23.
    Shin KH et al (1985) Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report. Cancer 56(4):758–760PubMedCrossRefGoogle Scholar
  24. 24.
    Fulton DS et al (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10:1709–1712PubMedGoogle Scholar
  25. 25.
    Shin KH, Muller PJ, Geggie PH (1983) Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer 52(11):2040–2043PubMedCrossRefGoogle Scholar
  26. 26.
    Payne DG et al (1982) Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 50(11):2301–2306PubMedCrossRefGoogle Scholar
  27. 27.
    Stuschke M, Thames HD (1997) Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37(2):259–267PubMedGoogle Scholar
  28. 28.
    Kleinberg L et al (1997) Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Rad Oncol Biol Phys 38(1):31–36Google Scholar
  29. 29.
    Bauman GS et al (1994) A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Rad Oncol Biol Phys 29(4):835–839Google Scholar
  30. 30.
    Sultanem K et al (2004) The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58(1):247–252PubMedCrossRefGoogle Scholar
  31. 31.
    Roa W et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22(9):1583–1588PubMedCrossRefGoogle Scholar
  32. 32.
    Hulshof MC et al (2000) Hypofractionation in glioblastoma multiforme. Radiother Oncol 54(2):143–148PubMedCrossRefGoogle Scholar
  33. 33.
    Ford JM et al (1997) A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 9(1):20–24Google Scholar
  34. 34.
    Hoegler DB, Davey P (1997) A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neuro-oncol 33(3):201–204CrossRefGoogle Scholar
  35. 35.
    Slotman BJ et al (1996) Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Rad Oncol Biol Phys 34(4):895–898Google Scholar
  36. 36.
    Thomas R et al (1994) Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 33(2):113–116PubMedCrossRefGoogle Scholar
  37. 37.
    Glinski B (1993) Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neuro-oncol 16(2):167–172CrossRefGoogle Scholar
  38. 38.
    Brada M et al (1999) Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Rad Oncol Biol Phys 43(2):287–292Google Scholar
  39. 39.
    Werner-Wasik M et al (1996) Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 77(8):1535–1543PubMedCrossRefGoogle Scholar
  40. 40.
    Horiot JC et al (1988) European organization for research on treatment of cancer trials using radiotherapy with multiple fractions per day. A 1978–1987 survey. Front Radiat Ther Oncol 22:149–161PubMedGoogle Scholar
  41. 41.
    Keim H et al (1987) Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiotherapy and Oncology : Radiother Oncol 9(1):21–26PubMedCrossRefGoogle Scholar
  42. 42.
    Simpson WJ, Platts ME (1976) Fractionation study in the treatment of glioblastoma multiforme. International Int J Radiat Oncol Biol Phys 1(7–8):639–644PubMedGoogle Scholar
  43. 43.
    Wen PY et al (1994) Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73(12):3029–3036PubMedCrossRefGoogle Scholar
  44. 44.
    Sneed PK et al (1998) Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40(2):287–295PubMedGoogle Scholar
  45. 45.
    Sneed PK et al (1995) Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 36(5):898–903 discussion 903–904PubMedCrossRefGoogle Scholar
  46. 46.
    Chang CN et al (2003) High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes. J Neurooncol 61(1):45–55PubMedCrossRefGoogle Scholar
  47. 47.
    Koot RW et al (2000) Brachytherapy: results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 88(12):2796–2802PubMedCrossRefGoogle Scholar
  48. 48.
    Videtic GM et al (2001) Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 51(4):963–968PubMedGoogle Scholar
  49. 49.
    Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6(3):227–235PubMedCrossRefGoogle Scholar
  50. 50.
    Laperriere NJ et al (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41(5):1005–1011PubMedGoogle Scholar
  51. 51.
    Selker RG et al (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51(2):343–355 discussion 355–357PubMedCrossRefGoogle Scholar
  52. 52.
    Chang CN et al (2003) High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes. J Neurooncol 61(1):45–55 PubMedCrossRefGoogle Scholar
  53. 53.
    Mayr MT et al (2002) Results of interstitial brachytherapy for malignant brain tumors. Int J Oncol 21(4): 817–823 PubMedGoogle Scholar
  54. 54.
    Curran WJ Jr et al (1993) Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyper-fractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11(5):857–862PubMedGoogle Scholar
  55. 55.
    Lustig RA, Scott CB, Curran WJ (2004) Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies? Am J Clin Oncol 27(5):516–521PubMedCrossRefGoogle Scholar
  56. 56.
    Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853–860PubMedGoogle Scholar
  57. 57.
    Masciopinto JE et al (1995) Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 82(4):530–535PubMedGoogle Scholar
  58. 58.
    Gannett D et al (1995) Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys 33(2):461–468PubMedGoogle Scholar
  59. 59.
    Buatti JM et al (1995) Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int J Radiat Oncol Biol Phys 32(1):205–210PubMedGoogle Scholar
  60. 60.
    Mehta MP et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30(3):541-549PubMedGoogle Scholar
  61. 61.
    Kondziolka D et al (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41(4):776–783 discussion 783–785PubMedCrossRefGoogle Scholar
  62. 62.
    Larson DA et al (1996) Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys 36(5):1045–1053PubMedGoogle Scholar
  63. 63.
    Sarkaria JN et al (1995) Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 32(4): 931–941PubMedGoogle Scholar
  64. 64.
    Cho KH et al (2004) Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme. Technol Cancer Res Treat 3(1):41–49Google Scholar
  65. 65.
    Nwokedi EC et al (2002) Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50(1):41–46 discussion 46–47PubMedCrossRefGoogle Scholar
  66. 66.
    Shrieve DC et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90(1):72–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • John Buatti
    • 1
  • Timothy C. Ryken
    • 2
  • Mark C. Smith
    • 3
  • Penny Sneed
    • 4
  • John H. Suh
    • 5
  • Minesh Mehta
    • 6
  • Jeffrey J. Olson
    • 7
  1. 1.Department of Radiation OncologyUniversity of IowaIowa CityUSA
  2. 2.Department of NeurosurgeryUniversity of Iowa College of MedicineIowa CityUSA
  3. 3.Department of Radiation OncologyUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  4. 4.Department of Radiation OncologyUniversity of CaliforniaSan FranciscoUSA
  5. 5.Department of Radiation OncologyCleveland Clinic FoundationClevelandUSA
  6. 6.Department of Radiation OncologyUniversity of WisconsinMadisonUSA
  7. 7.Department of NeurosurgeryEmory University School of MedicineAtlantaUSA

Personalised recommendations